One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...
Recursive Superintelligence, a startup founded by former leaders from Meta AI, Google DeepMind, OpenAI, and Salesforce AI, has emerged from stealth with $650 million in funding at a $4.65 billion ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...
Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...
SALT LAKE CITY(AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $117.5 million in its first quarter. The Salt Lake City-based company said it had a ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...
Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's. The ...
Recursion Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.21 versus an estimate of $-0.3. Revenue was up $30.99 million from the same period last year. During the previous ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results